Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
- DOI
- 10.1016/s2352-3018(26)00118-9
- Published
- 2026-08-07
- Container
- Lancet HIV
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2352-3018-26-00118-9,
title = {Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.},
author = {Tremblay C and Valea I and Ndiaye BP and Barry H and ElSherif M and Cooper C and Breeze JL and Cai Y and Ye L and Omole T and Halperin SA and Mboup S and Langley JM.},
year = {2026},
journal = {Lancet HIV},
doi = {10.1016/s2352-3018(26)00118-9},
url = {https://doi.org/10.1016/s2352-3018(26)00118-9}
}RIS
TY - JOUR TI - Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. AU - Tremblay C AU - Valea I AU - Ndiaye BP AU - Barry H AU - ElSherif M AU - Cooper C AU - Breeze JL AU - Cai Y AU - Ye L AU - Omole T AU - Halperin SA AU - Mboup S AU - Langley JM. PY - 2026 JO - Lancet HIV DO - 10.1016/s2352-3018(26)00118-9 UR - https://doi.org/10.1016/s2352-3018(26)00118-9 ER -
APA
C, T., I, V., BP, N., H, B., M, E., C, C., JL, B., Y, C., L, Y., T, O., SA, H., S, M., & JM., L. (2026). Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.. Lancet HIV. https://doi.org/10.1016/s2352-3018(26)00118-9
Source records
- europe-pmc · retrieved 2026-09-26T09:22:18.838Z